MANNKIND CORP (MNKD) Q3 2025 10-Q Quarterly Report
MANNKIND CORP (MNKD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
MANNKIND CORP Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $82.1M for Q3 FY25, up 17% YoY from $70.1M; Nine months revenue $237.0M, up 14% YoY from $208.7M
- • Commercial product gross margin 80% Q3 FY25 vs 84% in Q3 FY24; Nine months margin 80% vs 79% YoY
- • Best segment: Royalties $33.3M Q3 FY25 (+23% YoY); Worst: V-Go net revenue down 19% Q3, 11% YTD
- • Operating cash flow $26.2M YTD FY25 vs $19.9M YTD FY24, non-cash charges included $17.2M stock comp, $7.8M FX loss
- • Management expects liquidity sufficient for 12+ months; notes additional term loan for scPharma acquisition and rising SG&A expenses (+22%)
Risk Factors
- • New risk: Acquisition-related integration risk triggered by October 2025 scPharma purchase, including increased interest expense and potential net debt impact
- • Updated operational risk: Manufacturing complications and supply chain challenges intensified by tariffs and U.S.-China trade tensions affecting V-Go production
- • Regulatory risk: Inflation Reduction Act's $35 insulin copay limit for Medicare Part D beneficiaries starting 2023 impacting pricing and reimbursement environment
- • Commercial risk: Difficulty securing and maintaining skilled sales forces for two distinct physician target groups after scPharma acquisition
- • Financial risk: Increased leverage and debt service requirements due to acquisition debt, with uncertain access to additional capital on favorable terms
Get deeper insights on MANNKIND CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.